Incorporating Somatuline’s generic approval headwinds
07/01/22 -"Despite easing pandemic headwinds and recovering underlying markets, our EPS estimates reset lower as we take on board Somatuline’s sales erosion on account of the approval of its generic in the US. ..."
Pages
62
Language
English
Published on
07/01/22
You may also be interested by these reports :
17/01/22
GSK has rejected Unilever’s £50bn bid for the former’s Consumer Healthcare business. The British UK giant believes that the offer significantly ...
17/01/22
Moreover, with the possible monetisation of Consumer Healthcare, the firm should have sizeable resources at its disposal to expedite ...
17/01/22
Investors’ fatigue is the usual summary view about Bayer’s (Buy, Germany) share price, five years down the road of the Monsanto acquisition. Value ...
12/01/22
Unlike Smaller Pharmas’ lackluster performance (up 16% since the March 2020 lows vs. 73% gain for STOXX600) since the COVID-19 outbreak, Hikma (Buy, ...